Eribulin effective for earlier treatment of metastatic breast cancer
the ONA take:
According to a new study published in the Journal of Clinical Oncology, researchers have found eribulin is active and well tolerated as first-, second-, or third-line therapy in patients with metastatic breast cancer.
For the study, researchers sought to determine the activity of eribulin as an early treatment for metastatic breast cancer.
For the phase 3 study, researchers randomly assigned 1,099 women with metastatic breast cancer who had previously been treated with an anthracycline or a taxane to receive either capecitabine or eribulin as first-, second-, or third-line therapy for metastatic breast cancer.
Results showed that there was no statistical difference in overall survival between capecitabine and eribulin. In addition, a subset analysis found that eribulin may be especially active in those with triple negative metastatic breast cancer, a type of breast cancer that is particularly difficult to treat because it does not respond to hormonal therapy or HER2-targeted therapies.
The findings suggest that eribulin may have a role earlier in the course of the treatment of metastatic breast cancer.
Eribulin is active and well tolerated as first-, second-, or third-line therapy in patients with metastatic breast cancer.
Sign Up for Free e-newsletters
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS
- ASCO Endorses SIO Guideline for Integrative Therapies in Breast Cancer
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|